Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development

Lead Research Organisation: Liverpool School of Tropical Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
publication icon
Adolfi A (2019) Functional genetic validation of key genes conferring insecticide resistance in the major African malaria vector, . in Proceedings of the National Academy of Sciences of the United States of America

publication icon
Hong WD (2019) AWZ1066S, a highly specific anti- drug candidate for a short-course treatment of filariasis. in Proceedings of the National Academy of Sciences of the United States of America

 
Description External advice to major funder with regard to antimalarial drug discovery projects 2016 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Macrofilaricide Drug Accelerator (MacDA) 2015 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Member of the MMV External Scientific Advisory Board 2017 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Confidence in concept Oxford
Amount £45,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 06/2018
 
Description IVCC contract
Amount £75,000 (GBP)
Organisation IVCC 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2018 
End 03/2019
 
Description IVCC project award
Amount £18,000 (GBP)
Organisation IVCC 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 07/2018
 
Description IVCC-LITE contribution
Amount £10,000 (GBP)
Organisation IVCC 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 05/2018
 
Description Innovate UK
Amount £635,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start  
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 12/2019
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description MICA: Pre-Clinical Development of a Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
Amount £1,490,692 (GBP)
Funding ID MR/R025401/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2018 
End 02/2020
 
Description MRC P2D
Amount £11,700 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2017 
End 09/2018
 
Description MRC iCASE Studentship
Amount £120,000 (GBP)
Funding ID MR/P016197/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description PhD Scheme
Amount £98,000 (GBP)
Organisation Redx Pharma Plc 
Sector Private
Country United Kingdom
Start  
 
Description Prostaglandin I2 and endothelial function in cerebral malaria
Amount $1,000,000 (USD)
Funding ID 3392.02 
Organisation King Abdullah University of Science and Technology (KAUST) 
Sector Academic/University
Country Saudi Arabia
Start 04/2018 
End 03/2021
 
Description Research Grant, BMC: DPFS Full
Amount £947,594 (GBP)
Funding ID MR/S00467X/1 
Organisation MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) 
Sector Public
Country United Kingdom
Start 01/2019 
End 12/2022
 
Description Targeting the IL-33-inflammasome axis in therapy for cerebral malaria
Amount £665,875 (GBP)
Funding ID MR/R010099/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2018 
End 03/2021
 
Description UCSF
Amount £36,000 (GBP)
Organisation University of Oxford 
Department Oxford University Innovation
Sector Private
Country United Kingdom
Start 11/2017 
End 02/2019
 
Title GM mosquito with novel insecticide resistance mechanism 
Description We have generated a GM mosquito carrying an over expressed chemosensory protein which confers resistance to pyrethroid insecticide via a novel, presumably sequestration or enhanced transport mechanism. 
Type Of Material Model of mechanisms or symptoms - non-mammalian in vivo 
Year Produced 2018 
Provided To Others? Yes  
Impact This tool is made available to the IVCC to test their new range of chemicals for mosquito vector control. 
 
Title GM mosquitoes expressing specific P450s 
Description Generation of GM Anopheles Gambia mosquitoes over expressing specific insecticide metabolising P450s 
Type Of Material Model of mechanisms or symptoms - non-mammalian in vivo 
Year Produced 2018 
Provided To Others? Yes  
Impact Mosquitoes are being used for commercial testing of volatile compounds in a genetic background of high P450 metabolism. The work will inform policy on the use of volatile compounds for malaria control. 
 
Title Geneticaly modified mosquito line created overexpressing Glutathione S-Transferase 
Description We have created mosquito lines that overexpress a GST thought to be responsible for resistance to a number of insecticide classes. These can be tested against alternative novel and repurposed compounds to gauge the likelihood of resistance already in the field or that may develop rapidly against these compounds. 
Type Of Material Model of mechanisms or symptoms - non-mammalian in vivo 
Year Produced 2017 
Provided To Others? Yes  
Impact To date, the tool has shown that GST can give rise to resistance to diagnostic doses of DDT. This is the first time that a direct in vivo relationship between an insecticide and a GST has been documented 
 
Title Phage display library for Wolbachia proteins 
Description A phage display library has been produced that covers all of the proteins in the genome of the Wolbachia endosymbiont of the human parasite, Brugia malayi. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact The phage display library will provide another method for target identification of Wolbachia, distinct from the proteomic workflow already developed. This, therefore, will provide a means for confirming protein targets. 
 
Title Testing of endectocide compounds in artificial feeding systems 
Description We have developed novel assays to taste the effect of nitisinone, a tyrosine degradation inhibitor, in blood feeder insects without the use of animals. Novel methods of artificial feeding have even developed for several blood feeder insects, including tsetse flies, mosquitoes and sand flies. This methodology allows to test different drugs without the need of using experimental animals in line with the principles of the 3R (Replacement, Reduction and Refinement) 
Type Of Material Biological samples 
Year Produced 2017 
Provided To Others? No  
Impact And described above, this new method avoids the use of animals for testing endectocides like nitisinone, which save resources and further prevent the use of experimental animals. 
 
Description Developing the mouse model for research on cerebral malaria 
Organisation University of Manchester
Department Division of Infection, Immunity & Respiratory Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Dr Kevin Couper is an expert on murine models of cerebral malaria but these have recently been questioned in terms of their validity for developing human studies. My group has provided access to human in vitro models of cerebral malaria and pre-publication data for transcriptional changes associated with the interaction between the malaria parasite and human endothelium. By working together we have produced better information about the murine model and have used this to identify potential therapeutic pathways.
Collaborator Contribution Dr Kevin Couper - ECM model and insights into inflammation in mammalian hosts.
Impact A quantitative brain map of experimental cerebral malaria pathology. Strangward P, Haley MJ, Shaw TN, Schwartz JM, Greig R, Mironov A, de Souza JB, Cruickshank SM, Craig AG, Milner DA Jr, Allan SM, Couper KN. PLoS Pathog. 2017 Mar 8;13(3):e1006267. doi: 10.1371/journal.ppat.1006267
Start Year 2017
 
Description Development of novel compounds against intracellular bacteria 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution In partnership with Salvensis, we have selected and screened several novel compounds that inhibit growth of intracellular bacteria. Lifearc are involved in developing assays that will be used to demonstrate target-specificity. In-silico docking, literature research and 'wet-lab' testing of infected cells with compounds and toxicity analysis conducted by LSHTM.
Collaborator Contribution Salvensis have helped to access and select novel compounds based on our preliminary data of intracellular replication inhibitors. These compounds are screened on site at LSHTM. Salvensis will also perform medicinal chemistry optimisation of lead compounds as they are identified, and where necessary facilitate compound synthesis. LifeArc are providing advice on the development of assays to show target-specificity of selected compounds.
Impact To date, this partnership has identified two chemically-related lead compounds that show greater sensitivity and reduced toxicity against intracellular M. tuberculosis compared with the original compounds that provided the preliminary data for the CiC award.
Start Year 2017
 
Description Development of novel compounds against intracellular bacteria 
Organisation Salvensis
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution In partnership with Salvensis, we have selected and screened several novel compounds that inhibit growth of intracellular bacteria. Lifearc are involved in developing assays that will be used to demonstrate target-specificity. In-silico docking, literature research and 'wet-lab' testing of infected cells with compounds and toxicity analysis conducted by LSHTM.
Collaborator Contribution Salvensis have helped to access and select novel compounds based on our preliminary data of intracellular replication inhibitors. These compounds are screened on site at LSHTM. Salvensis will also perform medicinal chemistry optimisation of lead compounds as they are identified, and where necessary facilitate compound synthesis. LifeArc are providing advice on the development of assays to show target-specificity of selected compounds.
Impact To date, this partnership has identified two chemically-related lead compounds that show greater sensitivity and reduced toxicity against intracellular M. tuberculosis compared with the original compounds that provided the preliminary data for the CiC award.
Start Year 2017
 
Description Drug target deconvolution in the obligate intracellular bacterium, Wolbachia: a chemical proteomic route to discovering novel antibacterial targets 
Organisation AbbVie Inc
Country Global 
Sector Private 
PI Contribution We have set up regular conference calls with the team at AbbVie to discuss progress and gain insight from both the chemistry and the target enabling science and technologies teams in terms of optimising the workflow.
Collaborator Contribution Abbie have provide their time and expertise to advise and assist our team in the enabling science and technological approaches to optimise the workflow.
Impact Recommendations for enabling science and technology platforms to optimise the workflow
Start Year 2017
 
Description Drug target deconvolution in the obligate intracellular bacterium, Wolbachia: a chemical proteomic route to discovering novel antibacterial targets (2) 
Organisation Imperial College London
Department Department of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution We have provided technical expertise in Wolbachia biology and medicinal chemistry as well as the associated materials to optimise and test the chemical proteomic workflow.
Collaborator Contribution Our collaborators at Imperial College have provided technical expertise and training in chemical proteomic techniques, which has allowed us to further optimise and subsequently test our workflows.
Impact No outputs or outcomes yet. Collaboration is multi-disciplinary including medicinal chemistry, biology and bioinformatics expertise.
Start Year 2018
 
Description Effect of tyrosine detoxification inhibitors in sandflies 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution We contribute with our experience in administering the drugs to blood feeder insects and in the general experimental design. We also supplied the drug and contribute to cover the costs of these experiments, which have been done at the LSHTM facilities.
Collaborator Contribution Colleagues at LSTMH has tested the lethal effect that a tyrosine degradation inhibitor has in Lutzomyia longipalpis, vector of visceral leishmaniasis in the Americas. This is one of the two Lu. longipalpis colonies in the UK. The drug works well either in blood meals or in sugar meals, which is essential for designing new types of sugar baits. These experiments have involved the training of one MSc and BSc student.
Impact No outputs yet
Start Year 2017
 
Description Eisai compounds 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution We have developed an in vitro assay for endothelial barrier function using human primary microvascular endotheium and Plasmodium falciparum infected erythrcytes. We have already used this to screen a series of ten PAR1 modulators from Eisai Ltd, of which three have shown good inhibition of thrombin-induced endothelial barrier loss. This work is based on our long-term interest and research on malaria cytoadherence, and access to patient isolates will provide an invaluable resource to examine the breadth of the parasite/ endothelium effect.
Collaborator Contribution Eisai developed a series of PAR1 modulators as potential drugs. The ten compounds that we have access to have all been through initial lead optimisation and two have entered early stage clinical trials.
Impact The work is still in progress and the CIC award will allow us to test the three Eisai compounds plus two registered PAR1 inhibitors from other companies, for their ability to block endothelial barrier loss induced by the interaction with P. falciparum-infected erythrocytes.
Start Year 2013
 
Description GeneFirst 
Organisation Genefirst Ltd.
PI Contribution GeneFirst and LSTM have held joint training sessions. GeneFirst have imparted their knowledge on proprietary probe design for MLPA.
Collaborator Contribution We have entered into a research agreement to develop and evaluate molecular multiplex diagnostic for anti-microbial resistance and febrile illnesses.
Impact training in MLPA
Start Year 2017
 
Description Metabolomics analysis of Anopheles mosquitoes treated with tyrosine degradation inhibitors 
Organisation University of Glasgow
Department Institute of Infection, Immunity and Inflammation
Country United Kingdom 
Sector Academic/University 
PI Contribution Our team carried out with all mosquitoes assays and provided samples to the polyomics facilities (UoG) for mass-spec metabolomics analysis
Collaborator Contribution Non-targeted LC-MS metabolomics analysis
Impact Our teams are currently preparing a manuscript based on these analyses.
Start Year 2018
 
Description Metabolomics analysis of tsetse flies treated with tyrosine degradation inhibitors 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We use Glossina (tsetse fly) as a model to understand the biochemical changes induced by nitisinone, a tyrosine degradation inhibitor that kills all blood feeder (insect) vectors. We conducted a time-course experiment are we treated tsetse flies from our LSTM colony with sublethal doses of nitisinone. All the samples were processed in Liverpool and then were analysed mass-spectrometry to determine what metabolites were affected by the drug.
Collaborator Contribution Collaborators at the Crick Institute processed and analysed all samples for mass spectrometry analysis, including dataset interpretation.
Impact No output yet. Manuscript in preparation: Sterkel M. et al. 'Targeting tyrosine degradation as a novel vector control tool'.
Start Year 2017
 
Description Novel Salmonella vaccine, infection model 
Organisation Umea University
Country Sweden 
Sector Academic/University 
PI Contribution Our team has created novel vaccines against Salmonella Typhi and Paratyphi infections, based on a newly discovered antigen.
Collaborator Contribution The partner has established an infection model using a genetically recombinant bacterial strain, allowing to investigate the protective capacity of our vaccine.
Impact Work in progress, no output yet. The collaboration is multi-disciplinary: vaccinology, immunology, bacteriology, molecular bacteriology.
Start Year 2018
 
Description Novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution We have an expertise in preclinical vaccinology and designed and proposed the project and methodologies.
Collaborator Contribution Our partner has demonstrated that T-cells are induced during acute typhoid and paratyphoid fever in humans against the target antigen that we are proposing (Napolitani et al., manuscript in preparation). The partner will help in characterising the response induced by the vaccine.
Impact The partner provided data that support the project and the grant application.
Start Year 2017
 
Description PHE 
Organisation Public Health England
Country United Kingdom 
Sector Public 
PI Contribution Basic and applied research to be performed in vaccine development
Collaborator Contribution Use or reagents and assay development.
Impact TBC
Start Year 2018
 
Description PHE 
Organisation Public Health England
Country United Kingdom 
Sector Public 
PI Contribution Sharing protocols.
Collaborator Contribution Same.
Impact Ongoing.
Start Year 2019
 
Description Prospective liability of novel and repurposed compounds to metabolic resistance in An. gambiae 
Organisation IVCC
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Produced genetically modified mosquitoes that overexpress specific P450s that confer resistance to current insecticides
Collaborator Contribution Partners provide the interface to collaborate effective with multiple industrial partners to produce and test novel compounds to control vector populations. As a partnership we are testing whether these novel compounds are susceptible to metabolism by mosquitoes, and thus likely to be effective in the field. The work also tests whether related re-purposed compounds, likely to be cheaper, are as efficient as the novel compounds
Impact Interim report on the first phase of compound testing. Application for further funds to expand the work to other GM mosquito lines,
Start Year 2017
 
Description Prospective liability of novel and repurposed compounds to metabolic resistance in An. gambiae (2) 
Organisation Liverpool School of Tropical Medicine
Department Liverpool Insect Testing Establishment
PI Contribution We provide screened and sexed genetically modified mosquitoes to the facility so that they can test their resistance characteristics against novel and repurposed compounds
Collaborator Contribution The LITE facility commercially tests active ingredients and compounds for toxicity and repellency against a variety of mosquito species. It is supported by the IVCC in their quest to discover new compounds for malaria control.
Impact First set of assays performed that have produced an interim report on relative sensitivity to compounds.
Start Year 2017
 
Description Prospective liability of novel and repurposed compounds to metabolic resistance in An. gambiae (3) 
Organisation CE Bioscience Ltd
PI Contribution We lead a research project examining the genetics of insecticide resistance in msoquitoes. We perform functional genetic modification to examine the role of different gene families in resistacne phenotypes, in order to develop methods and compounds to overcome this resistance.
Collaborator Contribution The partners have developed a high throughput rapid screen of larval susceptibility to compounds based on image analysis of multiwell plates of larvae to monitor behaviour and death.
Impact Successful application for an MRC iCASE Studentship to develop the system further. The collaboration is multidisciplinary involving biological, physiochemcal and computational analysis to provide both qualitative and quantitative analysis.
Start Year 2017
 
Description Role of prostacyclins in cerebral malaria 
Organisation King Abdullah University of Science and Technology (KAUST)
Country Saudi Arabia 
Sector Academic/University 
PI Contribution This partnership uses the co-culture model developed in LSTM to understand new pathways to control endothelial inflammation.
Collaborator Contribution Institut Pasteur - construction of transgenic parasites for testing in co-culture models KAUST - analysis of samples and sequencing; bioinformatics
Impact None available yet
Start Year 2018
 
Description Role of prostacyclins in cerebral malaria 
Organisation Pasteur Institute, Paris
Country France 
Sector Academic/University 
PI Contribution This partnership uses the co-culture model developed in LSTM to understand new pathways to control endothelial inflammation.
Collaborator Contribution Institut Pasteur - construction of transgenic parasites for testing in co-culture models KAUST - analysis of samples and sequencing; bioinformatics
Impact None available yet
Start Year 2018
 
Description Typhoid_PK 
Organisation University of Oxford
Department Oxford Vaccine Group
Country United Kingdom 
Sector Academic/University 
PI Contribution We have set up and run PK assays on blood collected from patients with Typhoid fever from the Oxford Typhoid Live Challenge Model
Collaborator Contribution The Oxford Vaccine Group has collected and stored these samples LSTM has analysed the data Manuscript in preparation
Impact The laboratory work has now been completed and the data are being written up for publication. The Oxford group will consider whether they might use the live challenge platform for PK studies The collaborators are also considering an application for large scale PK studies using these data
Start Year 2017
 
Description Bluedot Festival; Can malaria be eliminated from the bluedot before we reach mars? 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Bluedot is an annual music/ science festival held at Jodrell Bank that attracts 12 - 15,000 people. The talk on recent advances in malaria control held in a 200 seater auditorium was near capacity and attracted a diverse audience and age range (toddlers to retired). The presentation generated a great deal of interest and questions, particularly from teenage/ early 20's people citing interests in career opportunities in tropical medicine.
Year(s) Of Engagement Activity 2018
URL https://www.discoverthebluedot.com/profile/can-malaria-be-eliminated-from-the-blue-dot-before-we-rea...
 
Description Institutional visit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited Speaker at the University of Saarland, Saarbrucken, Germany
Year(s) Of Engagement Activity 2017
 
Description Institutional visit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited Speaker at the Helmholtz Centre for Infection Research in Braunschweig, Germany
Year(s) Of Engagement Activity 2017
 
Description Invited Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Invited presentation at International Society for Neglected Tropical Diseases. Purpose was to give an overview of the project to a more general audience. This prompted networking with personnel from industry.
Year(s) Of Engagement Activity 2018
 
Description School entrepreneur visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Award winning school children that had invented and trying to market novel approaches to disease control visited the dept to examine the transgenic mosquito colonies we have generated that feature in this award.
Year(s) Of Engagement Activity 2018
 
Description Science Fair (Big Bang North West) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Members of the team attended the Big Bang North West, which is a STEM celebration for school children and part of a programme led by EngineeringUK. Big Bang events enable young people to discover the exciting and rewarding STEM based careers available in their local area via fun, interactive activities. As a result of our participation and discussions with students and teachers, several inquiries were made to LSTM regarding participation in future events and tours.
Year(s) Of Engagement Activity 2017,2018
URL https://www.allaboutstem.co.uk/
 
Description Science museum display 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact We have provided genetically modified mosquitoes to the National Science museum for display in the medicine galleries, to illustrate the potential for disease control.
Year(s) Of Engagement Activity 2018
 
Description Series of Rational Drug Discovery lectures (Undergraduate) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact To provide a better understanding how the students can translate their science / research activities to have more impact in terms of generating and developing products such as drugs, insecticides etc.
Year(s) Of Engagement Activity 2018
 
Description Series of rational drug discovery lectures (Post Graduate) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact To provide a better understanding how the students can translate their science / research activities to have mor eimpact in terms of generating and developing products such as drugs, insecticides etc.
Year(s) Of Engagement Activity 2018
 
Description Technology discussion 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact We discussed the new technology with a spin-out company under a confidentiality agreement. We have plans to submit a patent application once we have collected more data and the company may be interested in in-licensing the technology.
Year(s) Of Engagement Activity 2017
 
Description Visit to research facility 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact To provide description of the project to heads of Yunnan Institute of Parasitic Diseases to stimulate interests of future collaborations and exchange of students between Institutes
Year(s) Of Engagement Activity 2017
 
Description visit by fiction author 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Visit by author Christine Poulson to discuss mosquito work as a basis for a plot in forthcoming crime novel.
Year(s) Of Engagement Activity 2018